8.99
price down icon3.23%   -0.30
after-market After Hours: 8.99
loading
Fulcrum Therapeutics Inc stock is traded at $8.99, with a volume of 365.94K. It is down -3.23% in the last 24 hours and up +22.81% over the past month. Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
See More
Previous Close:
$9.29
Open:
$9.15
24h Volume:
365.94K
Relative Volume:
0.59
Market Cap:
$486.28M
Revenue:
$2.81M
Net Income/Loss:
$-97.34M
P/E Ratio:
-5.6899
EPS:
-1.58
Net Cash Flow:
$-91.47M
1W Performance:
+0.00%
1M Performance:
+22.81%
6M Performance:
+173.25%
1Y Performance:
+153.24%
1-Day Range:
Value
$8.82
$9.335
1-Week Range:
Value
$8.45
$9.89
52-Week Range:
Value
$2.315
$9.89

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name
Name
Fulcrum Therapeutics Inc
Name
Phone
617-651-8851
Name
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Name
Employee
45
Name
Twitter
@fulcrumtx
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
FULC's Discussions on Twitter

Compare FULC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
FULC
Fulcrum Therapeutics Inc
8.99 502.51M 2.81M -97.34M -91.47M -1.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
416.81 104.76B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
481.67 63.06B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
578.05 60.32B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
843.66 51.55B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
165.76 34.49B 398.11M -1.03B -868.57M -5.7032

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-29-25 Upgrade H.C. Wainwright Neutral → Buy
May-23-25 Upgrade Leerink Partners Market Perform → Outperform
May-15-25 Upgrade Cantor Fitzgerald Neutral → Overweight
Sep-13-24 Downgrade H.C. Wainwright Buy → Neutral
Sep-12-24 Downgrade BofA Securities Neutral → Underperform
Sep-12-24 Downgrade Cantor Fitzgerald Overweight → Neutral
Sep-12-24 Downgrade Leerink Partners Outperform → Market Perform
Sep-12-24 Downgrade RBC Capital Mkts Outperform → Sector Perform
Sep-12-24 Downgrade Stifel Buy → Hold
Sep-09-24 Upgrade BofA Securities Underperform → Neutral
May-20-24 Initiated Cantor Fitzgerald Overweight
Mar-13-24 Initiated RBC Capital Mkts Outperform
Sep-25-23 Initiated Goldman Neutral
Aug-23-23 Upgrade H.C. Wainwright Neutral → Buy
Aug-22-23 Upgrade Stifel Hold → Buy
May-04-23 Downgrade Goldman Buy → Neutral
Mar-10-23 Downgrade Credit Suisse Outperform → Neutral
Mar-10-23 Downgrade H.C. Wainwright Buy → Neutral
Mar-09-23 Downgrade Stifel Buy → Hold
Feb-28-23 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-24-23 Downgrade BofA Securities Neutral → Underperform
Nov-15-22 Initiated Goldman Buy
Mar-08-22 Initiated Oppenheimer Outperform
Mar-03-22 Upgrade BofA Securities Underperform → Neutral
Aug-11-21 Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-26-21 Resumed Credit Suisse Outperform
Mar-22-21 Initiated Credit Suisse Outperform
Mar-02-21 Initiated Stifel Buy
Oct-16-20 Initiated Piper Sandler Overweight
Aug-12-20 Downgrade BofA Securities Neutral → Underperform
Aug-12-20 Reiterated H.C. Wainwright Buy
Aug-12-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-19-20 Downgrade BofA/Merrill Buy → Neutral
Jun-17-20 Initiated BTIG Research Buy
Oct-03-19 Initiated H.C. Wainwright Buy
Aug-12-19 Initiated BofA/Merrill Buy
View All

Fulcrum Therapeutics Inc Stock (FULC) Latest News

pulisher
02:59 AM

How to track smart money flows in Fulcrum Therapeutics Inc.Earnings Risk Summary & High Accuracy Buy Signal Tips - newser.com

02:59 AM
pulisher
02:37 AM

What drives Fulcrum Therapeutics Inc stock priceShort Selling Opportunities & Low Cost Market Tips - earlytimes.in

02:37 AM
pulisher
02:11 AM

How supply chain issues affect Fulcrum Therapeutics Inc. stock2025 Breakouts & Breakdowns & Safe Capital Growth Plans - Trung tâm Dự báo KTTV quốc gia

02:11 AM
pulisher
11:39 AM

How to monitor Fulcrum Therapeutics Inc. with trend dashboardsJuly 2025 Sector Moves & Growth Focused Entry Reports - newser.com

11:39 AM
pulisher
11:18 AM

How Fulcrum Therapeutics Inc. stock reacts to Fed rate cuts2025 Biggest Moves & Safe Entry Zone Identification - Trung tâm Dự báo KTTV quốc gia

11:18 AM
pulisher
10:15 AM

Will Fulcrum Therapeutics Inc. stock outperform value stocksJuly 2025 Fed Impact & Low Risk High Reward Trade Ideas - Trung tâm Dự báo KTTV quốc gia

10:15 AM
pulisher
Oct 15, 2025

Can momentum traders help lift Fulcrum Therapeutics Inc.July 2025 Drop Watch & High Return Trade Opportunity Guides - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Real time alert setup for Fulcrum Therapeutics Inc. performance2025 Valuation Update & AI Based Buy and Sell Signals - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

How institutional buying supports Fulcrum Therapeutics Inc. stock2025 Analyst Calls & Safe Entry Point Identification - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Fulcrum Therapeutics Inc. stock volume spike explained2025 Dividend Review & Risk Controlled Daily Trade Plans - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

What risks investors should watch in Fulcrum Therapeutics Inc. stockRate Hike & Reliable Price Breakout Signals - newser.com

Oct 15, 2025
pulisher
Oct 14, 2025

Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025 - The Manila Times

Oct 14, 2025
pulisher
Oct 14, 2025

Fulcrum Therapeutics Presents Preclinical Data for FTX-6274 as a Potential Treatment for Castration-Resistant Prostate Cancer - Quiver Quantitative

Oct 14, 2025
pulisher
Oct 14, 2025

Pattern recognition hints at Fulcrum Therapeutics Inc. upsideJuly 2025 Analyst Calls & Daily Stock Trend Watchlist - newser.com

Oct 14, 2025
pulisher
Oct 14, 2025

FTX-6274 Poster 2504P: Fulcrum Shows Preclinical Efficacy in CRPC at ESMO Congress Oct 18, 2025 - Stock Titan

Oct 14, 2025
pulisher
Oct 14, 2025

Fulcrum Therapeutics Inc. stock outlook for YEAR2025 Technical Overview & Fast Momentum Stock Entry Tips - newser.com

Oct 14, 2025
pulisher
Oct 14, 2025

Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Price Target at $9.60 - Defense World

Oct 14, 2025
pulisher
Oct 13, 2025

Is Fulcrum Therapeutics Inc. stock poised for growthTrend Reversal & Low Risk Entry Point Guides - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

How to build a dashboard for Fulcrum Therapeutics Inc. stock2025 Short Interest & Reliable Price Action Trade Plans - newser.com

Oct 13, 2025
pulisher
Oct 12, 2025

What data driven models say about Fulcrum Therapeutics Inc.’s futureWeekly Stock Analysis & AI Driven Stock Movement Reports - newser.com

Oct 12, 2025
pulisher
Oct 11, 2025

What is Leerink Partnrs' Estimate for FULC FY2027 Earnings? - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

Leerink Partnrs Has Negative Outlook of FULC FY2027 Earnings - Defense World

Oct 11, 2025
pulisher
Oct 10, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq - MSN

Oct 10, 2025
pulisher
Oct 10, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 10, 2025
pulisher
Oct 10, 2025

Oklahoma City NewsThe Oklahoman - FinancialContent

Oct 10, 2025
pulisher
Oct 10, 2025

Detecting price anomalies in Fulcrum Therapeutics Inc. with AIIPO Watch & Low Drawdown Investment Strategies - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

What moving averages say about Fulcrum Therapeutics Inc.Portfolio Profit Report & Growth Oriented Trade Recommendations - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Order flow analysis tools used on Fulcrum Therapeutics Inc.2025 Short Interest & Daily Profit Focused Screening - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

Can Fulcrum Therapeutics Inc. recover in the next quarterProduct Launch & High Return Stock Watch Alerts - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Fulcrum Therapeutics Inc. stock momentum explainedQuarterly Profit Report & Fast Gain Swing Trade Alerts - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Fulcrum Therapeutics (NASDAQ:FULC) Given Sell (D-) Rating at Weiss Ratings - MarketBeat

Oct 09, 2025
pulisher
Oct 08, 2025

Fulcrum Therapeutics (NASDAQ:FULC) Reaches New 12-Month HighHere's What Happened - MarketBeat

Oct 08, 2025
pulisher
Oct 08, 2025

Fulcrum Therapeutics, Inc. $FULC Shares Sold by Matisse Capital - MarketBeat

Oct 08, 2025
pulisher
Oct 06, 2025

What does recent volatility data suggest for Fulcrum Therapeutics Inc.July 2025 Trends & Community Consensus Picks - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Technical analysis overview for Fulcrum Therapeutics Inc. stockTrade Ideas & Growth Focused Entry Reports - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Published on: 2025-10-05 20:19:33 - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Is Fulcrum Therapeutics Inc. stock trading near support levelsRate Cut & Safe Capital Growth Stock Tips - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

Using flow based indicators on Fulcrum Therapeutics Inc.Trade Entry Report & Free Low Drawdown Momentum Trade Ideas - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

Fulcrum Therapeutics Inc. recovery potential after sell offInflation Watch & Safe Entry Point Identification - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

What earnings revisions data tells us about Fulcrum Therapeutics Inc.Weekly Stock Report & Fast Moving Stock Watchlists - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

Can Fulcrum Therapeutics Inc. stock sustain market leadershipJuly 2025 Fed Impact & Safe Swing Trade Setup Alerts - newser.com

Oct 03, 2025

Fulcrum Therapeutics Inc Stock (FULC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$37.01
price up icon 1.84%
$87.57
price up icon 0.30%
$33.17
price up icon 1.28%
$105.14
price up icon 0.06%
biotechnology ONC
$316.42
price down icon 0.50%
$165.76
price up icon 1.57%
Cap:     |  Volume (24h):